Analysis originally distributed on June 21, 2017 By: Michael Vodicka of Cannabis Stock Trades
Legal cannabis scored another big victory this week.
In April, Mexico's lower parliament overwhelmingly voted to legalize medical cannabis, voting 357 to 7.
Then, earlier this week, Mexico's President Enrique Pena Nieto signed the bill into law, legalizing the use of medicinal cannabis THC, CBD, and all cannabis derivatives. The new legislation also makes it legal to produce and distribute cannabis for medical and therapeutic purposes.
Early estimates project sales between $1 billion and $2 billion in the first 10 years. That would come out to between $100 and $200 million per year.
The size of Mexico's young cannabis market will pale in comparison to the US and Canada.
In 2016, US cannabis sales totaled $6.5 billion. Continue reading "Mexico Legalizes Medical Cannabis - Here's How You Can Profit"
Analysis originally distributed on June 15, 2017 By: Michael Vodicka of Cannabis Stock Trades
In the old days, pot was seen as a way to get stoned.
But now, researchers are discovering that pot can actually have many health benefits.
Most of those come from Cannabidiol - one of the most prevalent compounds found in hemp plants that is commonly refereed to as CBD on the Street.
Studies have shown that the non-psychoactive elements of CBD can deliver relief to a wide range of ailments, including aches, pains, anxiety, insomnia and arthritis - without the euphoric effects provided by THC.
These benefits are creating a huge growth market.
The Hemp Business Journal, a CBD media and data company, estimates the CBD market will grow to $2.1 billion in consumer sales by 2020. That would be a 700% increase from 2016.
This is an exciting segment of the cannabis industry that doesn't get a lot of attention. Continue reading "Secret CBD Company Grows Sales 1,300% in 12 Months"
Analysis originally distributed on June 7, 2017 By: Michael Vodicka of Cannabis Stock Trades
Blockbuster drugs are the holy grail of the pharmaceutical and biotech industry.
When annual sales of a new drug break the $1 billion mark, investors are usually rewarded with big gains.
This is what began happening late 2012 with Gilead Science (NASDAQ:GILD).
In 2013 the FDA approved Gilead's hepatitis C drug Sovaldi.
Then, in 2014, Gilead scored an FDA approval for another Hep C drug, Harvoni.
Both drugs went on to quickly hit blockbuster status - sending shares of Gilead soaring - jumping more than 200% in the next two years. Take a look below.
Image courtesy of MarketClub.com
Today, the young cannabis industry is in hot pursuit of its first ever cannabis blockbuster - and I expect the winner of this race to deliver huge gains to shareholders. Continue reading "A 2nd Cannabis Stock With $1 Billion Drug Potential"
Analysis originally distributed on June 1, 2017 By: Michael Vodicka of Cannabis Stock Trades
Amazon was at the top of the headlines this week after its share price broke $1,000.
Amazon is now up 1,300% in the last 10 years. That is a nice win for shareholders. Early investors are sitting on big gains.
It’s also a reminder of where consumers are spending their money these days – online.
Any business that wants to thrive has to be winning online.
This is true in the cannabis industry. Just like the broader retail industry – online cannabis sales are booming.
However, Canada’s young cannabis companies are struggling to meet that growing demand.
To get the latest analysis as soon as it is released, please subscribe to our free weekly newsletter.
They are still being hampered by burdensome banking restrictions.
For example, Canadian cannabis producers have been banned from using PayPal because the U.S. based company is subject to US federal restriction on cannabis.
Even some larger banks have declined to provide financial service to Canada’s cannabis industry simply because its so new and considered higher risk. Continue reading "Will This Micro Cap Be The PayPal Of Canada's Cannabis Industry?"
Analysis originally distributed on May 24, 2017 By: Michael Vodicka of Cannabis Stock Trades
Investing in cannabis IPOs for the last few years has been extremely profitable.
Take Aphria Inc. (APHFQ), one of Canada's largest medical cannabis companies, for example.
Shares began trading on the Toronto Stock Exchange in October of 2015.
Now, just 18 months later, Aphria is up 499%. Take a look below.
Shares did get off to a slow start. And from there it wasn't a straight shot higher.
But as you can see, investors who bought early in the game are sitting on the biggest gains. And looking forward, early investors will still be collecting the biggest profits because they have the lowest cost basis.
If you're interested in profiting from future cannabis IPOs, you're in luck. Continue reading "Another 499% Gain In 18 Months On Tap?"